BCLSI
AVIR icon

Bain Capital Life Sciences Investors’s Atea Pharmaceuticals AVIR Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.65M Sell
2,075,639
-284,999
-12% -$1.42M 0.57% 18
2026
Q1 		$12.7M Sell
2,360,638
-125,000
-5% -$574K 1.15% 16
2025
Q4 		$8.87M Hold
2,485,638
– – 0.68% 16
2025
Q3 		$7.21M Hold
2,485,638
– – 0.48% 16
2025
Q2 		$8.95M Hold
2,485,638
– – 1.12% 16
2025
Q1 		$7.43M Hold
2,485,638
– – 1.1% 13
2024
Q4 		$8.33M Hold
2,485,638
– – 0.98% 16
2024
Q3 		$8.33M Hold
2,485,638
– – 0.87% 15
2024
Q2 		$8.23M Hold
2,485,638
– – 0.9% 17
2024
Q1 		$10M Hold
2,485,638
– – 0.81% 19
2023
Q4 		$7.58M Hold
2,485,638
– – 0.73% 21
2023
Q3 		$7.46M Hold
2,485,638
– – 0.83% 24
2023
Q2 		$9.3M Hold
2,485,638
– – 0.96% 22
2023
Q1 		$8.33M Hold
2,485,638
– – 1.04% 25
2022
Q4 		$12M Hold
2,485,638
– – 1.34% 21
2022
Q3 		$14.1M Hold
2,485,638
– – 1.69% 19
2022
Q2 		$17.6M Hold
2,485,638
– – 2.07% 16
2022
Q1 		$17.9M Hold
2,485,638
– – 1.74% 16
2021
Q4 		$22.2M Sell
2,485,638
-1,214,362
-33% -$18.9M 1.76% 15
2021
Q3 		$130M Sell
3,700,000
-1,915,659
-34% -$53.1M 8.05% 4
2021
Q2 		$121M Hold
5,615,659
– – 7.9% 2
2021
Q1 		$347M Hold
5,615,659
– – 19.64% 2
2020
Q4 		$235M Buy
+5,615,659
New +$181M 14.73% 2

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bain Capital Life Sciences Investors's AVIR Position: Q2 2026 in Review

Bain Capital Life Sciences Investors reduced its Atea Pharmaceuticals (AVIR) stake by 12% in Q2 2026, selling an estimated $1.42M and leaving 2,075,639 shares worth $9.65M. The position accounts for 0.57% of the portfolio, ranked #18.

Bain Capital Life Sciences Investors first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $347M in Q1 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Bain Capital Life Sciences Investors held 2,075,639 shares of Atea Pharmaceuticals worth $9.65M as of Q2 2026.
  • Bain Capital Life Sciences Investors sold 284,999 Atea Pharmaceuticals shares in Q2 2026, an estimated $1.42M.
  • Atea Pharmaceuticals made up 0.57% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #18 holding.
  • Bain Capital Life Sciences Investors first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Bain Capital Life Sciences Investors's Atea Pharmaceuticals position peaked at $347M in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.